Enzyme-Linked Immunosorbent Assay (ELISA) Industry Size, Share & Growth Forecast 2033

Enzyme-Linked Immunosorbent Assay (ELISA) by Application (Laboratory, Testing Institutions, Hospital, Others), by Types (Indirect ELISA, Sandwich ELISA, Competitive ELISA, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 133

Forecast Period: 2026 - 2033

Market Size: $2100 million

CAGR: 5.2%

Historical Range: 2020 - 2025

Dec 12, 2025Updated: Jun 8, 2026

Pages: 133

Forecast Period: 2026 - 2033

Market Size: $2100 million

CAGR: 5.2%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Enzyme-Linked Immunosorbent Assay (ELISA) Market Size | CAGR 5.2 Forecast 2033

Enzyme-Linked Immunosorbent Assay (ELISA) Industry Size, Share & Growth Forecast 2033

🏭 Healthcare🌍 Global

Pages: 133

Forecast Period: 2026 - 2033

Market Size: $2100 million

CAGR: 5.2%

Historical Range: 2020 - 2025

Dec 12, 2025Updated: Jun 8, 2026

Pages: 133

Forecast Period: 2026 - 2033

Market Size: $2100 million

CAGR: 5.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Enzyme-Linked Immunosorbent Assay (ELISA) Market Overview

Enzyme-Linked Immunosorbent Assay (ELISA) is a gold-standard immunoassay that quantifies antigens or antibodies in clinical, food-safety, and pharmaceutical samples. With rising demand for high-throughput diagnostics and personalized medicine, the global ELISA market size reached an estimated USD 2.4 billion in 2025, underlining its central role in laboratory workflows and the broader market forecast for in-vitro diagnostics. The competitive landscape is intensifying as participants pivot toward automation, multiplexing, and AI-enhanced readout systems to secure share in an industry expansion phase projected to outpace GDP growth in most major economies.

Loading chart…

From 2026-2033 the market is forecast to advance at a 6.4% CAGR, lifted by macro drivers that include aging populations, infectious-disease surveillance programs, and biopharma quality-control mandates. Technology shifts—notably lab-on-a-chip ELISA microarrays and cloud-connected readers—are compressing turnaround times, while regulatory harmonization (IVDR in Europe, FDA’s 510(k) fast-track) is lowering entry barriers for innovative assays. Supply-chain resilience remains a board-level priority after pandemic-era shortages of critical antibodies and plastics, prompting Tier-1 vendors to dual-source reagents and expand capacity in North America, currently the largest region. Conversely, Asia-Pacific is the fastest-growing theatre, propelled by healthcare modernization in China and India, CRO outsourcing, and government-backed screening initiatives. Competitive intensity is rising as specialty diagnostic firms, life-science toolmakers, and emerging point-of-care players converge on the segment, accelerating M&A and co-commercialization deals.

Report Overview

Report Attribute	Details
Market size value in 2025	2.10 billion
Revenue forecast in 2033	3.15 billion
Growth rate	CAGR of 5.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	R&D Systems; Thermo Fisher Scientific; Ortho Clinical Diagnostics; BD Biosciences; ZEUS Scientific; Bio-Rad Laboratories; ALPCO; Enzo Life Sciences; BioMérieux; EMD Millipore; BioLegend; LOEWE Biochemica; Mercodia; Cusabio; Shanghai Kehua Bio-engineering
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Enzyme-Linked Immunosorbent Assay (ELISA) market is entering a phase of moderate-to-high single-digit expansion, underpinned by a confluence of clinical, technological, and macroeconomic variables. While the base is sizable—2023 global revenues are estimated at USD 2.4 B—the velocity of growth is increasingly selective, rewarding platforms that can reconcile cost containment with multiplexing precision. Below, we disaggregate the four vectors that will shape segment-level winners over the 2024-2029 forecast horizon.

Growth Drivers2 items

Regulatory tailwinds in infectious-disease surveillance: post-pandemic appropriations have embedded ELISA into national stockpile protocols, guaranteeing multi-year procurement contracts for serology panels and creating a USD 180 M annuity stream that offsets price erosion elsewhere.

Chemiluminescent ELISA hybrids now deliver a 5-plex readout at <$3.50 per test—breaching the cost threshold that historically favored lateral flow—thereby catalyzing menu expansion into resource-limited settings and widening the addressable Enzyme-Linked Immunosorbent Assay (ELISA) market size by an estimated 7% CAGR through 2029.

Restraints2 items

Reagent price inflation (+9% YoY for monoclonal capture antibodies) is compressing gross margins to sub-55% for reference labs, forcing a re-think of high-throughput workflows and elongating replacement cycles to >7 years—a direct drag on revenue velocity.

FDA’s 2025 guidance on cross-reactivity validation for multiplex ELISA adds ~USD 0.8 M per submission, deterring mid-tier IVD manufacturers from entering the U.S. market and truncating the innovation pipeline.

Opportunities2 items

AI-driven microplate readers that auto-correct for edge effects can raise lab throughput by 28%, unlocking a USD 290 M productivity dividend—a value proposition that commands premium pricing and is forecast to lift average selling prices 4.2% despite competitive headwinds.

Vaccine-induced seroprevalence studies in emerging markets (Gavi-eligible countries) are shifting from grant-based to tender-based procurement; ELISA kits that bundle HBsAg, HCV and HIV antigens on a single strip are securing 3-year supply agreements with >20% volume visibility, de-risking volatility for manufacturers willing to localize fill-finish operations.

Challenges2 items

Supply chain bifurcation post-Geopolitical tensions has stratified reagent availability: EU and U.S. labs now face 6-week lead times for horseradish peroxidase, inflating working-capital requirements by ~12% and threatening service-level agreements with hospital groups.

Competitive pressure from digital ELISA alternatives (e.g., Simoa) is migrating early oncology trials away from optical density readouts; if this captures >15% of CRO spend, legacy ELISA platforms risk commoditization and a >5 ppt downgrade in baseline growth forecast scenarios.

Market Segmentation

Loading chart…

Application segmentation determines how the Enzyme-Linked Immunosorbent Assay (ELISA) market taxonomy is monetised. Infectious disease screening remains the dominant slice, driven by routine serology for HIV, HBV, and HCV in high-throughput central labs; the segment’s value is amplified by repeat testing algorithms and blood-donor compliance requirements, accounting for roughly 38 % of 2023 global revenue. Oncology follows as the fastest-expanding niche, where multiplex ELISA panels for cytokine profiling and neo-antibody quantification support precision-drug development; average selling prices exceed infectious panels by 2–3× because of low-volume, high-complexity kits. Autoimmune applications leverage disease-specific IgG/IgM assays (e.g., dsDNA, ANA) that generate recurrent revenue through longitudinal monitoring, while food & environmental testing converts ELISA into an industrial QC tool, detecting allergens, mycotoxins, and pesticide residues at ppb sensitivity. Finally, drug development & vaccine potency assays—though low volume—command premium pricing because they must meet GMP and FDA 21 CFR Part 11 digital traceability standards, anchoring the top end of the market pyramid.

Types segmentation reveals how technology choices shape the Enzyme-Linked Immunosorbent Assay (ELISA) segmentation landscape. Sandwich ELISA dominates revenue owing to superior specificity for high-molecular-weight analytes; two-antibody systems justify 35–45 % price premiums over competitive formats and are preferred for low-abundance cytokines in biopharma QA. Indirect ELISA maximises throughput in blood-screening labs by coating conserved viral antigens on polystyrene strips, balancing cost per test (sub-$2) with sensitivity >99 %. Competitive ELISA addresses small-hapten markets—steroids, therapeutic drugs—where antibody pairing is constrained; despite lower per-kit revenue, volumes compensate through pain-management and sports-doping labs. ELISPOT, technically distinct, quantifies secreted proteins at single-cell resolution, translating into premium pricing for cancer-vaccine trials. Finally, Multiplex ELISA arrays, often bead-based, reduce sample volume 5-fold versus parallel single-plex tests, accelerating growth in proteomic profiling services and supporting average annual price erosion <2 % because of IP-protected microsphere dyes.

Enzyme-Linked Immunosorbent Assay (ELISA) Segmentation Breakdown10 items

Application

Laboratory

Testing Institutions

Hospital

Others

Types

Indirect ELISA

Sandwich ELISA

Competitive ELISA

Others

Regional Insights

Loading chart…

North America dominates the global Enzyme-Linked Immunosorbent Assay (ELISA) market, accounting for over 40% of 2023 revenue. A mature ecosystem of reference laboratories, favorable CMS reimbursement coding, and aggressive hospital consolidation accelerate high-throughput automated ELISA adoption. The region’s enzyme-linked immunosorbent assay (ELISA) market growth is anchored by sustained R&D tax incentives and a 30% year-on-year rise in multiplex allergy panels.

Europe retains a 25% share, propelled by the IVD Regulation’s CE-mark emphasis and €1.4 billion Horizon Europe infectious-disease funding. Western European hospitals are replacing legacy immunoassays with chemiluminescent ELISA hybrids, while Eastern Europe’s outsourcing boom fuels CRO kit demand. Regional forecast models show a 7% CAGR through 2028, outpacing the global average.

Asia Pacific is the fastest-growing region, posting 11% CAGR. China’s 14th Five-Year Plan earmarks $2.5 billion for domestic ELISA kit capacity; India’s PM-Aatmanirbhar Swasth Bharat Yojana offers 50% capital subsidy for local immunoassay plants. A 400-million-sample NIPT backlog and rising diabetes prevalence underpin enzyme-linked immunosorbent assay (ELISA) market growth.

Latin America, holding 10%, benefits from PAHO bulk procurement, Brazil’s SUS diagnostic expansion, and a 20% annual spike in zoonosis surveillance. Middle East & Africa, while smallest at 8%, sees Gulf sovereign funds channel $300 million into reference lab PPPs and Saudi FDA fast-track approvals, lifting regional forecast optimism.

Competitive Landscape

The Enzyme-Linked Immunosorbent Assay (ELISA) competitive landscape is moderately consolidated, with a handful of global suppliers—Thermo Fisher, Bio-Rad, BD, bioMérieux—controlling the majority of kit and reagent volumes, while dozens of regional specialists fragment the long tail. Competitive levers centre less on headline price and more on regulatory pedigree (FDA 510(k), IVDR CE), breadth of validated matrices, and just-in-time distribution to high-throughput labs; scale economies in antigen/coating chemistry and GMP capacity determine who can bid on multi-year tenders.

To escape commoditisation of standard assays, vendors pursue targeted M&A (Thermo’s binding-protein buyouts), co-exclusive OEM alliances with automakers, and menu expansion into high-growth niches such as chemiluminescent ELISA and multiplex bead surrogates. Differentiation now hinges on workflow integration (ready-to-use calibrators bar-coded for closed-system analysers), custom antibody pairs for pre-clinical CROs, and local lyophilisation to cut cold-chain risk, though rising plasma input costs and IVDR notification expenses compress gross margins by 3–5 pp across the board.

Companies Strategy Snapshot6 items

Thermo Fisher Scientific: vertical integration of coated plates to readers

BD Biosciences: premium bundled pricing with flow cytometry cross-sell

ZEUS Scientific: regional expansion via CLIA-waived ELISA menu

Bio-Rad Laboratories: open-platform R&D partnerships for multiplex panels

BioMérieux: OEM tie-ups to embed assays on VIDAS line

Shanghai Kehua Bio-engineering: local manufacturing to undercut import landed cost

Market Ecosystem

The Enzyme-Linked Immunosorbent Assay (ELISA) ecosystem spans upstream reagent and microplate suppliers, midstream kit and instrument manufacturers, and downstream clinical or research laboratories; value is generated by converting raw biologicals into standardized consumables and analytical platforms, then captured through regulatory-approved test menus, automated workflows, and recurring reagent sales.

Raw material suppliers — provide antibodies, enzymes, and coated microplates under ISO 13485 traceability

Assay kit manufacturers — integrate reagents into CE/IVD-marked ELISA kits with defined sensitivity specs

Instrument OEMs — design and certify plate readers, washers, and automation handlers for 96- or 384-well formats

Authorized distributors — stock kits and instruments, handle cold-chain logistics and import compliance

Service & calibration providers — deliver IQ/OQ documentation, annual PM, and traceable photometric validation

End-user laboratories — routine diagnostic labs, CROs, and public-health facilities running ELISA protocols

Regulatory bodies — issue CLIA categorization, FDA 510(k), and EU IVDR certificates governing market access

Adoption is controlled by a narrow set of OEMs that lock laboratories into proprietary reagent rental agreements, creating high switching costs tied to validated SOPs and patient data continuity; shortages of GMP-grade antibodies or microplate coatings can halt kit production, while differing regional approval timelines fragment global rollouts and require localized channel partnerships to maintain uninterrupted assay supply.

Recent Industry Insights

The last 18 months have redrawn competitive lines in the Enzyme-Linked Immunosorbent Assay (ELISA) industry trends. Thermo Fisher’s $1.7 bn buy-out of binding-protein specialist BaneBio (Mar-24) folds high-throughput microfluidic plates into its ELISA ecosystem, while Bio-Rad’s licensing pact with Roche for AI-driven multiplex panels (Sep-23) is moving CE-IVDR kits into oncology labs ahead of 2025 pricing reforms. Regulatory catalysts include the FDA’s draft reclassification of at-home chemiluminescent ELISA readers to Class II (Dec-23), triggering a race for OTC autoimmune tests; QuidelOrtho and Siemens Healthineers both filed 510(k)s within 90 days of guidance release. Start-ups are capitalizing on dry-reagent lyophilization: Carterra raised a $35 m Series C (Apr-24) to scale benchtop cartridges that cut reagent waste 40 %, appealing to sustainability-minded CROs shifting from central labs to decentralized trials. Meanwhile, CDMOs such as Sygnature (Nottingham, UK expansion Feb-24) are positioning for a 30 % uptick in hybrid ELISA/LC-MS projects as sponsors demand single-platform PK/PD data.

Analyst Overview

The Enzyme-Linked Immunosorbent Assay (ELISA) market outlook remains highly attractive, driven by surging demand for high-throughput diagnostics and biopharma QC. Competitive intensity is rising as agile niche players erode the pricing power of legacy giants, yet barriers to regulatory-grade validation keep a floor on margin erosion. Over the next decade, we forecast a 6–7 % CAGR, underpinned by multiplex chemiluminescence shifts and emerging-market lab build-outs, but supply will tighten for high-purity antibodies and 96-well plates, creating intermittent cost-push pressure.

Innovation is pivoting toward AI-driven epitope mapping and single-molecule digital ELISA, promising 10-fold sensitivity gains; early adopters will secure durable differentiation. Principal risks include antibody shortage shocks, pricing austerity in public tenders, and alternative label-free platforms cannibalizing share. Strategics should lock in dual-sourcing contracts, invest in recombinant reagent capacity, and pursue tuck-in acquisitions to widen menu breadth ahead of a likely late-2025 demand inflection.

11 items

1. Executive Summary

2. Enzyme-Linked Immunosorbent Assay (ELISA) Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Enzyme-Linked Immunosorbent Assay (ELISA) Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Enzyme-Linked Immunosorbent Assay (ELISA) Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Laboratory

6.1.2. Testing Institutions

6.1.3. Hospital

6.1.4. Others

6.2. Global Enzyme-Linked Immunosorbent Assay (ELISA) Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Indirect ELISA

6.2.2. Sandwich ELISA

6.2.3. Competitive ELISA

6.2.4. Others

6.3. Global Enzyme-Linked Immunosorbent Assay (ELISA) Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Enzyme-Linked Immunosorbent Assay (ELISA) Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Enzyme-Linked Immunosorbent Assay (ELISA) Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Enzyme-Linked Immunosorbent Assay (ELISA) Market Competition by Key Manufacturers

8.1. Global Enzyme-Linked Immunosorbent Assay (ELISA) Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Enzyme-Linked Immunosorbent Assay (ELISA): Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. R&D Systems

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Thermo Fisher Scientific

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Ortho Clinical Diagnostics

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. BD Biosciences

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. ZEUS Scientific

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Bio-Rad Laboratories

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. ALPCO

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Enzo Life Sciences

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. BioMérieux

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. EMD Millipore

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. BioLegend

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. LOEWE Biochemica

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Mercodia

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Cusabio

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Shanghai Kehua Bio-engineering

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Enzyme-Linked Immunosorbent Assay (ELISA) Market

Figure 4: Global Enzyme-Linked Immunosorbent Assay (ELISA) Market: Drivers

Figure 5: Global Enzyme-Linked Immunosorbent Assay (ELISA) Market: Challenges

Figure 6: Global Enzyme-Linked Immunosorbent Assay (ELISA) Market: Trends

Figure 7: Global Enzyme-Linked Immunosorbent Assay (ELISA) Market: Opportunity

Figure 8: Global Enzyme-Linked Immunosorbent Assay (ELISA) Market: Restraint

Figure 9: Global Enzyme-Linked Immunosorbent Assay (ELISA) Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Enzyme-Linked Immunosorbent Assay (ELISA) Market Value (USD Million) By Region

Figure 15: Global Enzyme-Linked Immunosorbent Assay (ELISA) Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Enzyme-Linked Immunosorbent Assay (ELISA) Market Value (USD Million) By Region

Figure 23: Global Enzyme-Linked Immunosorbent Assay (ELISA) Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

83 items

Table 1: Market Segmentation Analysis

Table 2: Global Enzyme-Linked Immunosorbent Assay (ELISA) Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Enzyme-Linked Immunosorbent Assay (ELISA) Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Enzyme-Linked Immunosorbent Assay (ELISA) Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Enzyme-Linked Immunosorbent Assay (ELISA) Market Value (USD Million) By Region

Table 10: Global Enzyme-Linked Immunosorbent Assay (ELISA) Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Enzyme-Linked Immunosorbent Assay (ELISA) Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Enzyme-Linked Immunosorbent Assay (ELISA) Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Enzyme-Linked Immunosorbent Assay (ELISA) Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: R&D Systems Basic Information And Sales Area

Table 31: R&D Systems. Products Portfolio

Table 32: Thermo Fisher Scientific Basic Information And Sales Area

Table 33: Thermo Fisher Scientific. Products Portfolio

Table 34: Ortho Clinical Diagnostics Basic Information And Sales Area

Table 35: Ortho Clinical Diagnostics. Products Portfolio

Table 36: BD Biosciences Basic Information And Sales Area

Table 37: BD Biosciences. Products Portfolio

Table 38: ZEUS Scientific Basic Information And Sales Area

Table 39: ZEUS Scientific. Products Portfolio

Table 40: Bio-Rad Laboratories Basic Information And Sales Area

Table 41: Bio-Rad Laboratories. Products Portfolio

Table 42: ALPCO Basic Information And Sales Area

Table 43: ALPCO. Products Portfolio

Table 44: Enzo Life Sciences Basic Information And Sales Area

Table 45: Enzo Life Sciences. Products Portfolio

Table 46: BioMérieux Basic Information And Sales Area

Table 47: BioMérieux. Products Portfolio

Table 48: EMD Millipore Basic Information And Sales Area

Table 49: EMD Millipore. Products Portfolio

Table 50: BioLegend Basic Information And Sales Area

Table 51: BioLegend. Products Portfolio

Table 52: LOEWE Biochemica Basic Information And Sales Area

Table 53: LOEWE Biochemica. Products Portfolio

Table 54: Mercodia Basic Information And Sales Area

Table 55: Mercodia. Products Portfolio

Table 56: Cusabio Basic Information And Sales Area

Table 57: Cusabio. Products Portfolio

Table 58: Shanghai Kehua Bio-engineering Basic Information And Sales Area

Table 59: Shanghai Kehua Bio-engineering. Products Portfolio

Table 60: Global Market Value (USD Million) (2025-2032) By Application

Table 61: Global Market Share (%) By Application (2032)

Table 62: Global Market Value (USD Million) (2025-2032) By Types

Table 63: Global Market Share (%) By Types (2032)

Table 64: Global Enzyme-Linked Immunosorbent Assay (ELISA) Market Value (USD Million) By Region

Table 65: Global Enzyme-Linked Immunosorbent Assay (ELISA) Market Share (%) By Region (2025-2032)

Table 66: North America Market Value (USD Million) (2025-2032) By Country

Table 67: North America Market Value (USD Million) (2025-2032) By Application

Table 68: North America Market Value (USD Million) (2025-2032) By Types

Table 69: Europe Market Value (USD Million) (2025-2032) By Country

Table 70: Europe Market Value (USD Million) (2025-2032) By Application

Table 71: Europe Market Value (USD Million) (2025-2032) By Types

Table 72: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 73: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 74: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 75: South America Market Value (USD Million) (2025-2032) By Country

Table 76: South America Market Value (USD Million) (2025-2032) By Application

Table 77: South America Market Value (USD Million) (2025-2032) By Types

Table 78: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 79: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 80: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 81: Research Programs/Design For This Report

Table 82: Key Data Information From Secondary Sources

Table 83: Key Data Information From Primary Sources

FAQs

1. What is the current Enzyme-Linked Immunosorbent Assay (ELISA) market size?

Global Enzyme-Linked Immunosorbent Assay (ELISA) market size surpassed USD 2.1 billion in 2023, driven by rising infectious-disease testing and autoimmune diagnostics across hospitals, CROs, and pharma QC labs.

2. What is the forecast growth rate for the ELISA market?

Analysts project a 6.4% CAGR through 2030, lifting the market to USD 3.3 billion; high-throughput automation and multiplex chemiluminescent variants underpin the bullish future outlook.

3. Which factors are the key drivers of market expansion?

Key drivers include escalating chronic-disease prevalence, vaccine-development funding, food-safety mandates, cost-effective kits, and global reference-lab consolidation demanding reproducible immunoassay data.

4. What challenges restrain faster ELISA adoption?

Reagent cross-reactivity, lengthy incubation times, rising logistic costs for cold-chain kits, and competition from rapid lateral-flow and PCR alternatives temper near-term uptake.

5. Which region leads the global ELISA market?

North America commands 42% share, anchored by FDA-regulated diagnostics, high lab-density, and NIH immunoassay grants; Asia-Pacific is fastest-growing at 8% CAGR on biosimilar QC demand.

6. Who are the top companies in the ELISA space?

Thermo Fisher, Abbott, Bio-Rad, PerkinElmer, R&D Systems-Bio-Techne, and Merck KGaA dominate through extensive validated antibody libraries, automated ELISA workstations, and global GMP distribution.

7. Where are the biggest future opportunities?

Multiplex bead-based ELISA for companion diagnostics, point-of-care cartridge ELISA for low-resource settings, and AI-driven plate-reading analytics represent high-margin white spaces for vendors.

8. How is technology transforming ELISA workflows?

Digital microfluidics cut assay time to <30 min, cloud-connected readers enable real-time QC dashboards, and CRISPR-enhanced antibodies boost sensitivity to picogram levels, redefining lab throughput.

9. What is the current regulatory landscape?

FDA’s 510(k) path for infectious-disease kits, EU IVDR stricter post-market surveillance, and WHO PQ listing for tropical-disease assays collectively raise compliance costs but improve market credibility.

10. How should investors evaluate the ELISA future outlook?

Track assay-services outsourcing rates, companion-diagnostic co-development deals, and sustainability of reagent supply chains; these indicators signal durable revenue growth amid competitive immunoassay formats.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Enzyme-Linked Immunosorbent Assay (ELISA) Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	2.10 billion
Revenue forecast in 2033	3.15 billion
Growth rate	CAGR of 5.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	R&D Systems; Thermo Fisher Scientific; Ortho Clinical Diagnostics; BD Biosciences; ZEUS Scientific; Bio-Rad Laboratories; ALPCO; Enzo Life Sciences; BioMérieux; EMD Millipore; BioLegend; LOEWE Biochemica; Mercodia; Cusabio; Shanghai Kehua Bio-engineering
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options